European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Go back to European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 27.58 -0.44 (1.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.02 | 52 Week High | $42.49 | |||
| Open | $27.63 | 52 Week Low | $16.64 | |||
| Day High | $28.09 | P/E | N/A | |||
| Day Low | $27.10 | EPS | $-0.42 | |||
| Volume | 1,457,566 | |||||
